|
2023-09-25 |
2023-09-22 |
A
Achat
|
Rock Edwin
Chief Medical Officer
Dirigeant
|
30 403
+8.8%
1,38
41 956
USD
|
30 403
+8.8%
|
1,38
|
41 956
USD
|
|
|
2023-09-25 |
2023-09-21 |
A
Achat
|
Rock Edwin
Chief Medical Officer
Dirigeant
|
35 000
+11.3%
1,38
48 300
USD
|
35 000
+11.3%
|
1,38
|
48 300
USD
|
|
|
2023-05-18 |
2023-05-17 |
V
Vente
|
Hahn Brian M.
SVP Finance, CFO
Dirigeant
|
3 700
-6.5%
1,95
7 215
USD
|
3 700
-6.5%
|
1,95
|
7 215
USD
|
|
|
2023-05-11 |
2023-05-10 |
A
Achat
|
JUNIUS DANIEL M
Administrateur non-exécutif
|
30 000
+47.4%
1,56
46 800
USD
|
30 000
+47.4%
|
1,56
|
46 800
USD
|
|
|
2023-05-09 |
2023-05-08 |
A
Achat
|
Johnson Bruce S
SVP & Chief Commercial Officer
Dirigeant
|
13 500
+10.8%
1,57
21 195
USD
|
13 500
+10.8%
|
1,57
|
21 195
USD
|
|
|
2023-02-28 |
2023-02-24 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
100 000
+1.2%
1,70
170 000
USD
|
100 000
+1.2%
|
1,70
|
170 000
USD
|
|
|
2023-02-23 |
2023-02-23 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
200 000
+2.4%
1,75
350 760
USD
|
200 000
+2.4%
|
1,75
|
350 760
USD
|
|
|
2023-02-23 |
2023-02-22 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
150 000
+1.8%
1,79
268 995
USD
|
150 000
+1.8%
|
1,79
|
268 995
USD
|
|
|
2023-02-23 |
2023-02-21 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
50 000
+0.6%
1,85
92 500
USD
|
50 000
+0.6%
|
1,85
|
92 500
USD
|
|
|
2023-02-17 |
2023-02-17 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
200 000
+2.5%
1,71
341 000
USD
|
200 000
+2.5%
|
1,71
|
341 000
USD
|
|
|
2023-02-17 |
2023-02-16 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
315 266
+4.2%
1,68
531 129
USD
|
315 266
+4.2%
|
1,68
|
531 129
USD
|
|
|
2023-02-17 |
2023-02-15 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
1 000 000
+15.2%
2,16
2 155 800
USD
|
1 000 000
+15.2%
|
2,16
|
2 155 800
USD
|
|
|
2023-02-13 |
2023-02-09 |
A
Achat
|
Invus Public Equities, L.P.
Actionnaire important
|
11 451
+0.2%
3,24
37 123
USD
|
11 451
+0.2%
|
3,24
|
37 123
USD
|
|
|
2023-01-27 |
2023-01-26 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
1 351 092
-37.7%
3,12
4 213 786
USD
|
1 351 092
-37.7%
|
3,12
|
4 213 786
USD
|
|
|
2023-01-27 |
2023-01-26 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
1 648 908
-37.7%
3,12
5 142 614
USD
|
1 648 908
-37.7%
|
3,12
|
5 142 614
USD
|
|
|
2023-01-27 |
2023-01-25 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
293 645
-7.6%
3,26
958 428
USD
|
293 645
-7.6%
|
3,26
|
958 428
USD
|
|
|
2023-01-27 |
2023-01-25 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
358 371
-7.6%
3,26
1 169 687
USD
|
358 371
-7.6%
|
3,26
|
1 169 687
USD
|
|
|
2023-01-06 |
2023-01-05 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
32 139
-0.8%
2,76
88 659
USD
|
32 139
-0.8%
|
2,76
|
88 659
USD
|
|
|
2023-01-06 |
2023-01-05 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
39 223
-0.8%
2,76
108 201
USD
|
39 223
-0.8%
|
2,76
|
108 201
USD
|
|
|
2023-01-04 |
2023-01-04 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
45 930
-1.2%
2,91
133 643
USD
|
45 930
-1.2%
|
2,91
|
133 643
USD
|
|
|
2023-01-04 |
2023-01-04 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
56 054
-1.2%
2,91
163 100
USD
|
56 054
-1.2%
|
2,91
|
163 100
USD
|
|
|
2023-01-04 |
2023-01-03 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
78 730
-1.9%
2,99
235 411
USD
|
78 730
-1.9%
|
2,99
|
235 411
USD
|
|
|
2023-01-04 |
2023-01-03 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
96 084
-1.9%
2,99
287 301
USD
|
96 084
-1.9%
|
2,99
|
287 301
USD
|
|
|
2023-01-04 |
2022-12-30 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
54 645
-1.3%
3,02
165 028
USD
|
54 645
-1.3%
|
3,02
|
165 028
USD
|
|
|
2023-01-04 |
2022-12-30 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
66 690
-1.3%
3,02
201 404
USD
|
66 690
-1.3%
|
3,02
|
201 404
USD
|
|
|
2022-12-27 |
2022-12-22 |
A
Achat
|
Rock Edwin
Chief Medical Officer
Dirigeant
|
110 000
+55.0%
2,25
247 500
USD
|
110 000
+55.0%
|
2,25
|
247 500
USD
|
|
|
2022-11-18 |
2022-11-17 |
A
Achat
|
JUNIUS DANIEL M
Administrateur non-exécutif
|
20 000
+46.2%
1,87
37 400
USD
|
20 000
+46.2%
|
1,87
|
37 400
USD
|
|
|
2022-11-16 |
2022-11-15 |
A
Achat
|
Rock Edwin
Chief Medical Officer
Dirigeant
|
100 000
+100.0%
1,66
166 000
USD
|
100 000
+100.0%
|
1,66
|
166 000
USD
|
|
|
2022-11-16 |
2022-11-14 |
A
Achat
|
Rock Edwin
Chief Medical Officer
Dirigeant
|
100 000
+inf%
1,43
143 000
USD
|
100 000
+inf%
|
1,43
|
143 000
USD
|
|
|
2022-11-14 |
2022-11-11 |
A
Achat
|
PEARSON TIMOTHY R
Administrateur non-exécutif
|
19 400
+369.5%
1,29
25 026
USD
|
19 400
+369.5%
|
1,29
|
25 026
USD
|
|
|
2022-11-14 |
2022-11-11 |
A
Achat
|
Semerjian Harout
Chief Executive Officer
Administrateur exécutif
|
25 000
+inf%
1,29
32 250
USD
|
25 000
+inf%
|
1,29
|
32 250
USD
|
|
|
2022-11-14 |
2022-11-11 |
A
Achat
|
Hahn Brian M.
SVP Finance, CFO
Dirigeant
|
20 000
+54.3%
1,06
21 200
USD
|
20 000
+54.3%
|
1,06
|
21 200
USD
|
|
|
2022-11-14 |
2022-11-11 |
A
Achat
|
Girard Armand
SVP, Chief Business Officer
Dirigeant
|
6 500
+28.7%
1,05
6 825
USD
|
6 500
+28.7%
|
1,05
|
6 825
USD
|
|
|
2022-11-14 |
2022-11-11 |
A
Achat
|
Magnani John L.
SVP of Research, CSO
Dirigeant
|
45 045
+14.0%
1,17
52 703
USD
|
45 045
+14.0%
|
1,17
|
52 703
USD
|
|
|
2022-03-10 |
2022-03-09 |
V
Vente
|
Hahn Brian M.
SVP Finance, CFO
Dirigeant
|
2 917
-7.3%
1,09
3 180
USD
|
2 917
-7.3%
|
1,09
|
3 180
USD
|
|
|
2022-03-10 |
2022-03-09 |
V
Vente
|
Magnani John L.
SVP of Research, CSO
Dirigeant
|
3 227
-1.0%
1,09
3 517
USD
|
3 227
-1.0%
|
1,09
|
3 517
USD
|
|
|
2022-03-10 |
2022-03-09 |
V
Vente
|
Girard Armand
SVP, Chief Business Officer
Dirigeant
|
2 339
-9.4%
1,09
2 550
USD
|
2 339
-9.4%
|
1,09
|
2 550
USD
|
|
|
2021-11-18 |
2021-11-16 |
A
Achat
|
Andrews Patricia S
Administrateur non-exécutif
|
40 000
+761.9%
2,05
82 000
USD
|
40 000
+761.9%
|
2,05
|
82 000
USD
|
|
|
2020-12-30 |
2020-12-28 |
VP
Vente planifiée
|
King Rachel K.
President, CEO
Administrateur exécutif
|
84 176
-19.1%
3,91
329 128
USD
|
84 176
-19.1%
|
3,91
|
329 128
USD
|
|
|
2020-11-06 |
2020-11-04 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
86 090
+15.8%
2,60
223 834
USD
|
86 090
+15.8%
|
2,60
|
223 834
USD
|
|
|
2020-11-06 |
2020-11-04 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
506 155
+15.8%
2,60
1 316 003
USD
|
506 155
+15.8%
|
2,60
|
1 316 003
USD
|
|
|
2020-11-06 |
2020-11-04 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
674 492
+15.7%
2,60
1 753 679
USD
|
674 492
+15.7%
|
2,60
|
1 753 679
USD
|
|
|
2020-11-03 |
2020-10-30 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
15 472
+2.9%
2,75
42 548
USD
|
15 472
+2.9%
|
2,75
|
42 548
USD
|
|
|
2020-11-03 |
2020-10-30 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
250 755
+8.5%
2,75
689 576
USD
|
250 755
+8.5%
|
2,75
|
689 576
USD
|
|
|
2020-11-03 |
2020-10-30 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
666 385
+18.3%
2,75
1 832 559
USD
|
666 385
+18.3%
|
2,75
|
1 832 559
USD
|
|
|
2020-03-10 |
2020-03-09 |
A
Achat
|
JUNIUS DANIEL M
Administrateur non-exécutif
|
20 000
+111.1%
3,40
68 000
USD
|
20 000
+111.1%
|
3,40
|
68 000
USD
|
|
|
2019-09-09 |
2019-09-05 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
124 956
+30.9%
3,18
397 610
USD
|
124 956
+30.9%
|
3,18
|
397 610
USD
|
|
|
2019-09-09 |
2019-09-05 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
689 834
+30.4%
3,18
2 195 052
USD
|
689 834
+30.4%
|
3,18
|
2 195 052
USD
|
|
|
2019-09-09 |
2019-09-05 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
853 956
+30.7%
3,18
2 717 288
USD
|
853 956
+30.7%
|
3,18
|
2 717 288
USD
|
|
|
2019-08-15 |
2019-08-13 |
A
Achat
|
JUNIUS DANIEL M
Administrateur non-exécutif
|
10 000
+125.0%
3,18
31 800
USD
|
10 000
+125.0%
|
3,18
|
31 800
USD
|
|
|
2018-10-18 |
2018-10-18 |
V
Vente
|
Magnani John L.
SVP of Research, CSO
Administrateur exécutif
|
3 527
-4.4%
14,02
49 449
USD
|
3 527
-4.4%
|
14,02
|
49 449
USD
|
|
|
2018-10-18 |
2018-10-17 |
V
Vente
|
Magnani John L.
SVP of Research, CSO
Administrateur exécutif
|
7 273
-8.4%
14,00
101 822
USD
|
7 273
-8.4%
|
14,00
|
101 822
USD
|
|
|
2018-10-18 |
2018-10-16 |
V
Vente
|
Magnani John L.
SVP of Research, CSO
Administrateur exécutif
|
14 200
-14.1%
14,01
198 942
USD
|
14 200
-14.1%
|
14,01
|
198 942
USD
|
|
|
2018-06-12 |
2018-06-11 |
V
Vente
|
Hahn Brian M.
CFO
|
19 345
-100.0%
18,04
348 984
USD
|
19 345
-100.0%
|
18,04
|
348 984
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
BARRIS PETER J
Actionnaire important
|
5 533
-0.1%
17,81
98 543
USD
|
5 533
-0.1%
|
17,81
|
98 543
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
BARRIS PETER J
Actionnaire important
|
4 006
-0.1%
17,81
71 347
USD
|
4 006
-0.1%
|
17,81
|
71 347
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
5 533
-0.1%
17,81
98 543
USD
|
5 533
-0.1%
|
17,81
|
98 543
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
4 006
-0.1%
17,81
71 347
USD
|
4 006
-0.1%
|
17,81
|
71 347
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
BARRETT M JAMES
Administrateur non-exécutif
Actionnaire important
|
5 533
-0.1%
17,81
98 543
USD
|
5 533
-0.1%
|
17,81
|
98 543
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
BARRETT M JAMES
Administrateur non-exécutif
Actionnaire important
|
4 006
-0.1%
17,81
71 347
USD
|
4 006
-0.1%
|
17,81
|
71 347
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
NEW ENTERPRISE ASSOCIATES 10 L P
Actionnaire important
|
5 533
-0.1%
17,81
98 543
USD
|
5 533
-0.1%
|
17,81
|
98 543
USD
|
|
|
2018-05-11 |
2018-05-10 |
V
Vente
|
NEW ENTERPRISE ASSOCIATES 10 L P
Actionnaire important
|
4 006
-0.1%
17,81
71 347
USD
|
4 006
-0.1%
|
17,81
|
71 347
USD
|
|
|
2017-12-12 |
2017-12-08 |
V
Vente
|
Thackray Helen M.
SVP Clinical Development, CMO
|
2 000
-1.3%
15,01
30 020
USD
|
2 000
-1.3%
|
15,01
|
30 020
USD
|
|
|
2017-09-18 |
2017-09-18 |
V
Vente
|
Thackray Helen M.
SVP Clinical Development, CMO
|
2 000
-1.3%
13,00
26 000
USD
|
2 000
-1.3%
|
13,00
|
26 000
USD
|
|
|
2017-05-30 |
2017-05-25 |
V
Vente
|
Thackray Helen M.
SVP Clinical Development, CMO
Dirigeant
|
2 000
-1.3%
15,57
31 140
USD
|
2 000
-1.3%
|
15,57
|
31 140
USD
|
|
|
2017-05-22 |
2017-05-19 |
VP
Vente planifiée
|
Thackray Helen M.
SVP Clinical Development, CMO
Dirigeant
|
2 000
-1.3%
12,14
24 280
USD
|
2 000
-1.3%
|
12,14
|
24 280
USD
|
|
|
2016-12-21 |
2016-12-20 |
A
Achat
|
JUNIUS DANIEL M
Administrateur non-exécutif
|
5 000
+inf%
6,01
30 050
USD
|
5 000
+inf%
|
6,01
|
30 050
USD
|
|
|
2016-10-04 |
2016-10-03 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
100
-0.1%
7,01
701
USD
|
100
-0.1%
|
7,01
|
701
USD
|
|
|
2016-10-04 |
2016-10-03 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
3 900
-2.4%
7,00
27 300
USD
|
3 900
-2.4%
|
7,00
|
27 300
USD
|
|
|
2016-07-21 |
2016-07-20 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
2 000
-1.2%
8,00
16 000
USD
|
2 000
-1.2%
|
8,00
|
16 000
USD
|
|
|
2016-07-06 |
2016-07-06 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
6 796
-4.0%
6,68
45 397
USD
|
6 796
-4.0%
|
6,68
|
45 397
USD
|
|
|
2016-07-06 |
2016-07-05 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
10 136
-5.6%
7,01
71 053
USD
|
10 136
-5.6%
|
7,01
|
71 053
USD
|
|
|
2016-07-06 |
2016-07-01 |
VP
Vente planifiée
|
Thackray Helen M.
VP Clinical Development, CMO
Dirigeant
|
5 068
-2.7%
7,40
37 503
USD
|
5 068
-2.7%
|
7,40
|
37 503
USD
|
|
|
2016-03-07 |
2016-03-04 |
A
Achat
|
Goldberg Mark Alan
Administrateur non-exécutif
|
10 397
+945.2%
4,77
49 630
USD
|
10 397
+945.2%
|
4,77
|
49 630
USD
|
|
|
2015-11-18 |
2015-11-16 |
V
Vente
|
NEW ENTERPRISE ASSOCIATES 10 L P
Actionnaire important
|
452
-0.0%
6,91
3 123
USD
|
452
-0.0%
|
6,91
|
3 123
USD
|
|
